Pierrel S.p.A. | Balance Sheet

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
Cash & Short Term Investments
3,357.00
4,461.00
1,218.00
1,108.00
1,850.00
Total Accounts Receivable
11,747.00
9,404.00
4,406.00
3,757.00
3,531.00
Inventories
3,563.00
3,421.00
2,271.00
2,574.00
2,881.00
Other Current Assets
648.00
617.00
28,852.00
5,486.00
932.00
Total Current Assets
19,315.00
17,903.00
36,747.00
12,925.00
9,194.00
Net Property, Plant & Equipment
13,848.00
14,445.00
10,969.00
10,223.00
10,216.00
Total Investments and Advances
-
50.00
204.00
280.00
133.00
Long-Term Note Receivable
83.00
16.00
4.00
4.00
4.00
Intangible Assets
29,612.00
24,610.00
1,496.00
1,407.00
1,403.00
Other Assets
2,136.00
-
-
-
-
Total Assets
71,475.00
63,456.00
54,816.00
30,246.00
26,225.00
ST Debt & Current Portion LT Debt
23,716.00
22,712.00
8,113.00
16,464.00
2,566.00
Accounts Payable
13,514.00
10,420.00
5,617.00
5,839.00
4,486.00
Income Tax Payable
1,738.00
2,088.00
1,245.00
912.00
384.00
Other Current Liabilities
8,774.00
8,478.00
15,758.00
4,429.00
3,983.00
Total Current Liabilities
47,742.00
43,698.00
30,733.00
27,644.00
11,419.00
Long-Term Debt
10,772.00
9,183.00
20,343.00
7,519.00
10,726.00
Provision for Risks & Charges
1,496.00
1,674.00
342.00
350.00
350.00
Deferred Taxes
5,461.00
4,882.00
5,341.00
5,407.00
5,275.00
Other Liabilities
1,131.00
47.00
2,434.00
2,243.00
1,476.00
Total Liabilities
62,161.00
56,152.00
53,907.00
37,756.00
23,971.00
Common Equity (Total)
642.00
15,208.00
17,392.00
7,510.00
2,254.00
Total Shareholders' Equity
642.00
15,208.00
17,392.00
7,510.00
2,254.00
Total Equity
9,314.00
7,304.00
909.00
7,510.00
2,254.00
Liabilities & Shareholders' Equity
71,475.00
63,456.00
54,816.00
30,246.00
26,225.00
Accumulated Minority Interest
8,672.00
22,512.00
18,301.00
-
-

About Pierrel

View Profile
Address
Strada Statale Appia 7-bis 46/48
Capua Caserta 81043
Italy
Employees -
Website http://www.pierrelgroup.com
Updated 09/14/2018
Pierrel SpA engages in the clinical research of medicinal product candidates. It operates through the following business divisions: Tech-driven Contract Research & Development Organization (TCRDO), Contract Manufacturing, and Pharma. The TCRDO division focuses on the repositioning of existing drugs in new indications.